New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
05:53 EDTALXNAlexion price target raised to $205 from $125 at Deutsche Bank
Deutsche Bank raised its price target for shares of Alexion Pharmaceuticals to $205 citing upside potential from the company's launch of Asfotase Alfa for severe Hypophosphatasia. The firm keeps a Buy rating on the stock.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
05:28 EDTALXNAlexion receives approval for updates to EU label for Solaris
Subscribe for More Information
April 7, 2015
17:38 EDTALXNAlexion CEO Dr. Leonard Bell retired as of March 31
Dr. Leonard Bell, the principal founder and CEO of Alexion Pharmaceuticals retired from Alexion effective March 31, after serving as CEO for twenty-three years. No severance was paid to Dr. Bell in connection with his retirement. On April 1, Alexion entered into a Consulting Agreement and a Letter Agreement with Dr. Bell. Dr. Bell continues to serve as Alexion's Chairman of the Board of Directors.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use